Bovine lactoferrin and its tryptic peptides: Antibacterial activity against different species


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

The research of new antimicrobial compounds has an impact on public health and economy of many countries. Given the great problem of bacterial resistance, the study of new molecules that bypass this mechanism is of great importance. Trypsin is an enzyme necessary for gut physiology and the peptides it forms could be of great interest to the pharmaceutical industry. In this study the antibacterial activity of undigested and trypsin-hydrolyzed iron-depleted form of lactoferrin, (apo-bLf) and undigested and diferric bovine lactoferrin (bLf) were evaluated against different bacterial species. Apo-bLf was less susceptible to trypsin hydrolysis compared to the diferric form and its tryptic fragments with molecular weight lower than 5000 Da had greater activity than those obtained from the diferric-bLf. It is plausible that the antimicrobial activity is exerted mainly by the interaction of the N-terminal moiety of the protein with the bacterial cell. The in silico analysis of the interdomain movements, showed that the conformation of the active N-terminal part of apo-bLf is more open than that of the diferric form. The increased accessibility of the N-terminal region seems to be responsible for the antimicrobial activity of the apo-bLf and its tryptic fragments.

About the authors

A. R. Lizzi

Department of Biotechnological and Applied Clinical Sciences

Author for correspondence.
Email: arlizzi@cc.univaq.it
Italy, Coppito 2, Via Vetoio, L’Aquila, I-67100

V. Carnicelli

Department of Biotechnological and Applied Clinical Sciences

Email: arlizzi@cc.univaq.it
Italy, Coppito 2, Via Vetoio, L’Aquila, I-67100

M. M. Clarkson

Department of Biotechnological and Applied Clinical Sciences

Email: arlizzi@cc.univaq.it
Italy, Coppito 2, Via Vetoio, L’Aquila, I-67100

C. Nazzicone

Department of Biotechnological and Applied Clinical Sciences

Email: arlizzi@cc.univaq.it
Italy, Coppito 2, Via Vetoio, L’Aquila, I-67100

B. Segatore

Department of Biotechnological and Applied Clinical Sciences

Email: arlizzi@cc.univaq.it
Italy, Coppito 2, Via Vetoio, L’Aquila, I-67100

G. Celenza

Department of Biotechnological and Applied Clinical Sciences

Email: arlizzi@cc.univaq.it
Italy, Coppito 2, Via Vetoio, L’Aquila, I-67100

M. Aschi

Department of Physical and Chemical Sciences

Email: arlizzi@cc.univaq.it
Italy, Coppito 1, Via Vetoio, L’Aquila, I-67100

V. Dolo

Department of Life, Health and Environmental Sciences

Email: arlizzi@cc.univaq.it
Italy, Coppito 2, Via Vetoio, L’Aquila, I-67100

R. Strom

Department of Cellular Biotechnologies and Haematology

Email: arlizzi@cc.univaq.it
Italy, Rome, I-00161

G. Amicosante

Department of Biotechnological and Applied Clinical Sciences

Email: arlizzi@cc.univaq.it
Italy, Coppito 2, Via Vetoio, L’Aquila, I-67100

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2016 Pleiades Publishing, Inc.